0.74
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Monash IVF Group
Its shares trade on ASX under the ticker MVF.AX. It has been listed since 25 June 2014. In the fiscal year to 30 June 2026, it reported revenue of A$269.5m and net income of A$7.4m. At that date it held total assets of A$512.4m and shareholders' equity of A$249.2m.
Monash IVF Group Ltd. engages in the field of fertility services. The company is headquartered in Richmond, Victoria. The company went IPO on 2014-06-25. The firm is also engaged in the provision of women's imaging and diagnostic services in Australia and Malaysia. The firm's segments include Monash IVF Group Australia and Monash IVF Group International. The Monash IVF Group Australia segment is a provider of assisted reproductive services, ultrasound and other related services. The Monash IVF Group International segment is a provider of assisted reproductive services in Malaysia. The firm offers a range of specialist diagnostic obstetric and gynecological ultrasound and fertility treatments. The firm's business includes Bump, KL Fertility, Monash Ultrasound for Women, MyIVF Clinic, Next Generation Fertility, Reproductive Medicine Albury, Reproductive Medicine Wagga, Repromed and Sydney Ultrasound for Women. Bump provides patients with a personalized online application tool, iBUMP.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 25 Jun 2014
- Employees
- 537
- Website
- monashivfgroup.com.au ↗
Leadership
Pay as last reported
- Mr. Richard DavisNon-Executive Independent Chairman of the BoardA$183,694
- Mr. Malik JainudeenActing Chief Executive Officer, Company Secretary, since 2025A$583,848
- Mr. Andrew MaclachlanInterim Chief Financial Officer
- Mr. Hamish HamiltonChief Operating Officer, since 2020A$608,353
- Dr. Richard HenshawExecutive DirectorA$393,899
- Ms. Catherine AstonNon-Executive Independent DirectorA$35,884
- Mr. Neil BroekhuizenNon-Executive Independent DirectorA$107,654
- Ms. Zita PeachNon-Executive Independent DirectorA$117,030
- Ms. Catherine WestNon-Executive Independent DirectorA$107,653
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 69
- Social
- 80
- Governance
- 44
- Women in the workforce
- 92%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Monash IVF Group Ltd is a renowned and respected reproductive healthcare provider, with a strong reputation and track record in the industry.
- The company has built a recognized brand name and enjoys a significant market presence, providing a competitive advantage in attracting patients and healthcare professionals.
- Monash IVF Group offers a broad range of reproductive services, including fertility treatments, genetic screening, donor programs, and specialized diagnostic procedures. This extensive service offering caters to a wide range of patient needs.
Weaknesses
- Monash IVF Group's primary revenue stream comes from assisted reproductive technology, making the company vulnerable to any decline in demand or changes in government regulations related to this field.
- The reproductive healthcare industry is subject to strict regulations and oversight. Any changes in regulations, compliance requirements, or licensing conditions may impact the company's operations and financial performance.
- The cost of reproductive treatments and associated procedures can be relatively high, making it less accessible for certain individuals or causing potential financial strain on patients.
Opportunities
- There is an increasing demand for reproductive services due to various factors such as delayed pregnancies, changing lifestyles, and rising infertility rates. Monash IVF Group can leverage this growth opportunity by expanding its service offerings and geographic reach.
- Advancements in reproductive technology and genetic testing provide opportunities for Monash IVF Group to enhance its offerings, improve success rates, and develop innovative solutions to address patients' needs.
Threats
- The reproductive healthcare industry is highly competitive, with numerous local and international providers. Monash IVF Group faces the risk of losing market share to competitors offering similar services or attractive pricing strategies.
- Fluctuations in the economy, changes in healthcare funding, and insurance coverage can impact demand for reproductive services, potentially affecting Monash IVF Group's financial performance.
- Reproductive healthcare involves sensitive ethical and legal considerations such as embryo storage, surrogacy agreements, and genetic manipulation. Non-compliance or controversies related to these areas could harm the company's reputation and create legal challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.